A Proof‑of‑concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure

Sponsor ID
351-201-00015
Clinicaltrials.gov ID
NCT06795399
EudraCT ID
N/A
EUCTIS ID
N/A
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information
N/A
Terminated/Withdrawn
Sponsor ID
351-201-00015
Trial Details
Subscribe for updates
Age
18+ years
Therapeutic Area
  • Heart Disease/Heart Failure
    • Sex
    Female & Male
    Trial Dates
    Apr 2025 - May 2025
    Healthy Volunteers
    No
    • Diagnosis of HF ≥ 3 months prior to screening.
    • Admitted to the hospital with primary diagnosis of WHF and received treatment with intravenous (IV) diuretics.
    • Eligible participants will be randomized no earlier than 48 hours and up to 5 days after presentation to the hospital as long as they meet the following definition of stable status: Stable for at least 24 hours, defined by systolic blood pressure (SBP) ≥ 90 millimeters of mercury (mmHg) for preceding 24 hours, no increase in diuretic dose for 24 hours prior to randomization, did not receive IV inotropic or vasodilator (including nitrates) for 24 hours prior to randomization, and no oxygen therapy or mechanical ventilation in the 24 hours prior to randomization
    • Left ventricular ejection fraction (LVEF) assessed either during hospitalization for Index Event or within 12 months prior to randomization.
    • Has evidence of incomplete decongestion, indicated by NT-proBNP levels \> 750 picograms per milliliter (pg/mL) (or \> 1000 pg/mL if in atrial fibrillation). At hospital sites where NT proBNP test is unavailable at screening: B-type natriuretic peptide (BNP) \> 375 pg/mL (or \> 500 pg/mL if in atrial fibrillation).
    • Primary cause of WHF (Index Event) due to valvular heart disease (defined as severe aortic or primary mitral regurgitation, moderate or severe aortic stenosis, any mitral stenosis requiring surgical repair, or active endocarditis), congenital heart disease, hypertrophic obstructive cardiomyopathy, pulmonary embolism, Type I myocardial infarction, infection, severe anemia, exacerbation of chronic obstructive pulmonary disease (COPD), or sustained ventricular tachycardia, or bradycardia with sustained ventricular rate \< 45 beats/minute.
    • Duration of hospitalization for Index Event \> 2 weeks at time of screening.
    • End-stage HF requiring at the time of screening left ventricular assist device (LVAD), intra-aortic balloon pump (IABP) or any similar mechanical support.
    • Cardiac surgery (coronary artery bypass grafting \[CABG\]), percutaneous coronary intervention (PCI), implantation of a cardiac device or cardiac mechanical support implantation within 30 days prior to randomization or planned during the study
    • Severely impaired renal function eGFR \< 25 milliliters per minute per 1.73-meter square (mL/min/1.73m\^2).
    • History of dialysis or kidney transplant.
    • History of cirrhosis or noncirrhotic portal hypertension.
    • Severe hyponatremia Sodium (Na) level \< 125 mEq/L (milliequivalents per liter) or hypernatremia Na level \> 145 mEq/L).
    • Systolic blood pressure \< 90 mmHg at screening.
    • History of or current hepatitis or acquired immunodeficiency syndrome or carriers of hepatitis B surface antigen (HBsAg) and/or hepatitis C antibodies (anti-HCV), or human immunodeficiency virus (HIV) antibodies.
    • History of any significant drug allergy or known or suspected hypersensitivity to any component of the study drug.
    • Use of any investigational drug within 30 days prior to screening.
    • History of serious mental disorders that, in the opinion of the investigator, would exclude the participant from participating in this trial.
    • Note: Other protocol-specified inclusion and exclusion criteria may apply.

    Study Summary

    The primary objective of the study is to compare relative changes in blood N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels after 30 days of treatment in participants with worsening heart failure (WHF), who are treated with either OPC-131461 or placebo.

    Additional Study Details

    Phase
    Phase 2
    Study Drug
    Drug: OPC-131461
    Type
    Interventional
    Masking
    Double
    Estimated Enrollment
    N/A
    Additional Study Details

    Inclusion and Exclusion Criteria

    Inclusion Criteria

    • * Diagnosis of HF ≥ 3 months prior to screening.
    • * Admitted to the hospital with primary diagnosis of WHF and received treatment with intravenous (IV) diuretics.

    Exclusion Criteria

    • * Primary cause of WHF (Index Event) due to valvular heart disease (defined as severe aortic or primary mitral regurgitation, moderate or severe aortic stenosis, any mitral stenosis requiring surgical repair, or active endocarditis), congenital heart disease, hypertrophic obstructive cardiomyopathy, pulmonary embolism, Type I myocardial infarction, infection, severe anemia, exacerbation of chronic obstructive pulmonary disease (COPD), or sustained ventricular tachycardia, or bradycardia with sustained ventricular rate \< 45 beats/minute.
    • * Duration of hospitalization for Index Event \> 2 weeks at time of screening.
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    • Diagnosis of HF ≥ 3 months prior to screening.
    • Admitted to the hospital with primary diagnosis of WHF and received treatment with intravenous (IV) diuretics.
    • Eligible participants will be randomized no earlier than 48 hours and up to 5 days after presentation to the hospital as long as they meet the following definition of stable status: Stable for at least 24 hours, defined by systolic blood pressure (SBP) ≥ 90 millimeters of mercury (mmHg) for preceding 24 hours, no increase in diuretic dose for 24 hours prior to randomization, did not receive IV inotropic or vasodilator (including nitrates) for 24 hours prior to randomization, and no oxygen therapy or mechanical ventilation in the 24 hours prior to randomization
    • Left ventricular ejection fraction (LVEF) assessed either during hospitalization for Index Event or within 12 months prior to randomization.
    • Has evidence of incomplete decongestion, indicated by NT-proBNP levels \> 750 picograms per milliliter (pg/mL) (or \> 1000 pg/mL if in atrial fibrillation). At hospital sites where NT proBNP test is unavailable at screening: B-type natriuretic peptide (BNP) \> 375 pg/mL (or \> 500 pg/mL if in atrial fibrillation).
    Exclusion Criteria:
    • Primary cause of WHF (Index Event) due to valvular heart disease (defined as severe aortic or primary mitral regurgitation, moderate or severe aortic stenosis, any mitral stenosis requiring surgical repair, or active endocarditis), congenital heart disease, hypertrophic obstructive cardiomyopathy, pulmonary embolism, Type I myocardial infarction, infection, severe anemia, exacerbation of chronic obstructive pulmonary disease (COPD), or sustained ventricular tachycardia, or bradycardia with sustained ventricular rate \< 45 beats/minute.
    • Duration of hospitalization for Index Event \> 2 weeks at time of screening.
    • End-stage HF requiring at the time of screening left ventricular assist device (LVAD), intra-aortic balloon pump (IABP) or any similar mechanical support.
    • Cardiac surgery (coronary artery bypass grafting \[CABG\]), percutaneous coronary intervention (PCI), implantation of a cardiac device or cardiac mechanical support implantation within 30 days prior to randomization or planned during the study
    • Severely impaired renal function eGFR \< 25 milliliters per minute per 1.73-meter square (mL/min/1.73m\^2).
    • History of dialysis or kidney transplant.
    • History of cirrhosis or noncirrhotic portal hypertension.
    • Severe hyponatremia Sodium (Na) level \< 125 mEq/L (milliequivalents per liter) or hypernatremia Na level \> 145 mEq/L).
    • Systolic blood pressure \< 90 mmHg at screening.
    • History of or current hepatitis or acquired immunodeficiency syndrome or carriers of hepatitis B surface antigen (HBsAg) and/or hepatitis C antibodies (anti-HCV), or human immunodeficiency virus (HIV) antibodies.
    • History of any significant drug allergy or known or suspected hypersensitivity to any component of the study drug.
    • Use of any investigational drug within 30 days prior to screening.
    • History of serious mental disorders that, in the opinion of the investigator, would exclude the participant from participating in this trial.
    • Note: Other protocol-specified inclusion and exclusion criteria may apply.

    Locations

    No locations found.

    © 2026 Otsuka America Pharmaceutical, Inc.

    All rights reserved.

    January 2026 01US25EUC0489

    We defy limitation,

    so that others can too.

    Follow Us
    OAPI and OPDC Locations

    508 Carnegie Center Dr,

    Princeton, NJ 08540, United States

    Phone +1 609-524-6788

    2440 Research Blvd,

    Rockville, MD 20850, United States

    Phone +1 301-424-9055

    3956 Point Eden Way

    Hayward, CA 94545, United States

    Phone +1 800-562-3974